Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0851
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus ; day:11 ; month:2 ; year:2019 ; pages:1-12
Cancer immunology immunotherapy ; (11.2.2019), 1-12
- Creator
-
Werter, Inge M.
Huijts, Charlotte M.
Lougheed, Sinéad. M.
Hamberg, Paul
Polee, Marco B.
Tascilar, Metin
Los, Maartje
Haanen, John B. A. G.
Helgason, Helgi H.
Verheul, Henk M.
Gruijl, Tanja D. de
Vliet, Hans J. van der
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-019-02313-z
- URN
-
urn:nbn:de:101:1-2019031500101621577930
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Werter, Inge M.
- Huijts, Charlotte M.
- Lougheed, Sinéad. M.
- Hamberg, Paul
- Polee, Marco B.
- Tascilar, Metin
- Los, Maartje
- Haanen, John B. A. G.
- Helgason, Helgi H.
- Verheul, Henk M.
- Gruijl, Tanja D. de
- Vliet, Hans J. van der
- SpringerLink (Online service)
Other Objects (12)
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
mTOR inhibitor everolimus reduces invasiveness of melanoma cells
mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
mTOR inhibitor everolimus reduces invasiveness of melanoma cells
mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
mTOR inhibitor everolimus reduces invasiveness of melanoma cells
mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex